Epoxide Hydrolase Inhibitor

Arabinothalictoside is found in A. squamosa L. Arabinothalictoside is a sEH inhibitor (IC₅₀: 47.1 µM). Arabinothalictoside can be used in the research of cardiovascular and urinary diseases.

DJ-89 (Compound 77) is a potent soluble epoxide hydrolase (sEH) inhibitor with an IC₅₀ value of 0.51 nM . DJ-89 inhibits sEH from hydrolyzing epoxyeicosatrienoic acids (EETs), reducing the production of pro-inflammatory substances. DJ-89 is promising for research of acute and chronic inflammatory diseases (such as rheumatoid arthritis).

sEH/AChE-IN-4 (compound (+)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC₅₀ values of 3.1 nM (hsEH), 1660 nM (hAChE), 179 nM (hBChE, human butyrylcholinesterase), 14.5 nM (msEH), and 102 nM (mAChE), respectively.

N-(3-Methoxybenzyl)stearamide a natural product from Lepidium meyenii (Maca), inhibits human and mouse soluble epoxide hydrolase (hsEH and msEH) with IC₅₀s of 0.001 and <0.001 μg/nM, respectively.

BRP-821 is a soluble epoxide hydrolase (sEH) inhibitor with an IC₅₀ of 0.4 nM. BRP-821 can be used for the researches of inflammation, cardiovascular, metabolic and neurological disease .

Epoxykynin is a potent epoxide hydrolase (sEH) inhibitor.

sEH-IN-21 is an orally active sEH inhibitor with IC₅₀s of 0.1 nM for hsEH and msEH. sEH-IN-21 potently inhibits NF-κB signaling pathways. sEH-IN-21 shows a strong anti-inflammatory activity, decreases the release of IL-6 and TNF-α and maintained the integrity of the intestinal barrier. sEH-IN-21 can be used for the study of inflammatory bowel disease (IBD).

sEH inhibitor-11 (compound 35) is a sEH inhibitor with an IC₅₀ value of 0.3 μM. sEH inhibitor-11 can be used for the research of inflammation.

sEH/PPARδ modulator 1 is a sEH/PPARδ dual modulator. sEH/PPARδ modulator 1 can inhibit sEH with an IC₅₀ of 0.46 μM and activate PPARδ with an EC₅₀ of 0.12 μM. sEH/PPARδ modulator 1 can be used for the researches of inflammation, metabolic and cardiovascular disease.

sEH-IN-25 is an orally active soluble epoxide hydrolase (epoxide hydrolase) inhibitor, with an IC₅₀ of 0.5 nM against human sEH and an IC₅₀ of 2 nM against rat sEH. sEH-IN-25 can be used in the research of cardiovascular diseases.

Alisol B (Standard) is the analytical standard of Alisol B (HY-N0805A). This product is intended for research and analytical applications. Alisol B is a triterpene with diverse biological activities. Alisol B binds human soluble epoxide hydrolase (sEH) with a K_i of 5.97 μM and reduces sEH activity. Alisol B inhibits RANKL-induced JNK phosphorylation, NFATc1 and c-Fos expression, osteoclast formation, mature osteoclast pit-forming and actin ring activity, and SERCA pump activity. Alisol B induces calcium mobilization, CaMKK-AMPK-mTOR pathway activation, autophagic flux, autophagosome formation, G1 phase cell cycle arrest, endoplasmic reticulum stress, unfolded protein responses, and cancer cell apoptosis. Alisol B can be used for the research of hypercalcemia, osteoporosis, rheumatoid arthritis, periodontitis, acute kidney injury, and breast cancer.

sEH-IN-3 (Compound 50) is a soluble epoxide hydrolase (sEH) inhibitor (IC₅₀: 0.46 nM). sEH-IN-3 can maintain the anti-inflammatory and analgesic activities of epoxyeicosatrienoic acids (EETs).

Soluble epoxide hydrolase inhibitor is an inhibitor of soluble epoxide hydrolase, and inhibits human soluble epoxide hydrolase (h-sEH) with pIC₅₀ of 8.4, extracted from patent WO 2010096722 A1, example 57.

sEH-IN-26 is a urea structure-based soluble epoxide hydrolase (sEH) inhibitor with selectivity for mammalian cytosolic and peroxisomal sEH. sEH-IN-26 can be used for the research of inflammation and epoxide hydrolase-related diseases.

sEH inhibitor-20 is an orally active and metabolically stable sEH inhibitor (IC₅₀: 0.2 nM). sEH inhibitor-20 has significant analgesic and anti-inflammatory activities and is expected to become a potential candidate compound for the study of neuropathic pain.

Valpromide (Standard) is the analytical standard of Valpromide (HY-B2117). This product is intended for research and analytical applications. Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle.

AUDA (Standard) is the analytical standard of AUDA. This product is intended for research and analytical applications. AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively. AUDA has anti-inflammatory activity.

TPPU (Standard) is the analytical standard of TPPU (HY-101294). This product is intended for research and analytical applications. TPPU is a soluble epoxide hydrolase (sEH) inhibitor with IC50 values of 37 and 3.7 nM for monkey and human sEH, respectively.

LQ-38 is an orally active inhibitor for soluble epoxide hydrolase (sEH) with an IC₅₀ of 5.2 nM. LQ-38 exhibits anti-inflammatory activity in rat foot edema model and mouse acute pancreatitis model, exhibits analgesic effect in Acetic acid (HY-Y0319)-induced writhing mouse model.

CUDA-d₁₁ is deuterium labeled CUDA (HY-121538). CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease.